Last updated: April 5, 2025
Sponsor: Thammasat University Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Knee Replacement
Osteoarthritis
Treatment
Pregabalin
Mirogabalin
Clinical Study ID
NCT06328062
TUH Mirogabalin TKA
Ages 50-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age 50-85 years old
Unilateral primary osteoarthritis undergoing primary TKA
ASA I-III
Exclusion
Exclusion Criteria:
GFR <60
Allergy to drug in this study
Cannot underwent spinal anesthesia and adductor canal block
Taking gabapentinoid within 3 months before surgery
History of previous knee surgery
Severe liver disease
Study Design
Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Pregabalin
Phase:
Study Start date:
April 01, 2024
Estimated Completion Date:
May 31, 2025
Study Description
Connect with a study center
Thammasat University Hospital
Khlong Luang, Pathum Thani 12120
ThailandActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.